Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Olema Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Olema Pharmaceuticals, Inc.’s stock price such as:

• Olema Pharmaceuticals, Inc.’s current stock price and volume
• Why Olema Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for OLMA from analysts
• OLMA’s stock price momentum as measured by its relative strength

About Olema Pharmaceuticals, Inc. (OLMA)

Before we jump into Olema Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Want to learn more about Olema Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Olema Pharmaceuticals, Inc..

Olema Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of April 10, 2026, 4:00 PM, CST, Olema Pharmaceuticals, Inc.’s stock price was $16.100.

Olema Pharmaceuticals, Inc. is down 3.25% from its previous closing price of $16.640.

During the last market session, Olema Pharmaceuticals, Inc.’s stock traded between $15.780 and $16.900. Currently, there are approximately 91.32 million shares outstanding for Olema Pharmaceuticals, Inc..

Olema Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Olema Pharmaceuticals, Inc. Stock Price History

Olema Pharmaceuticals, Inc.’s (OLMA) price is currently up 7.98% so far this month.

During the month of April, Olema Pharmaceuticals, Inc.’s stock price has reached a high of $16.990 and a low of $14.616.

Over the last year, Olema Pharmaceuticals, Inc. has hit prices as high as $36.259 and as low as $3.300. Year to date, Olema Pharmaceuticals, Inc.’s stock is down 35.6%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Olema Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 10, 2026, there was 1 analyst who downgraded Olema Pharmaceuticals, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Olema Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Olema Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Olema Pharmaceuticals, Inc. (OLMA) by visiting AAII Stock Evaluator.

Relative Price Strength of Olema Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 10, 2026, Olema Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 42.71%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Olema Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Olema Pharmaceuticals, Inc. Stock Price: Bottom Line

As of April 10, 2026, Olema Pharmaceuticals, Inc.’s stock price is $16.100, which is down 3.25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Olema Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.